Aurobindo Pharma Ltd. News and Updates

Name: Latest research reports of Aurobindo Pharma Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Aurobindo Pharma Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Keep track of all breaking news on Aurobindo Pharma Ltd. from all sources in a single place.

Load latest

Aurobindo Pharma Ltd.

29 Mar 2022

1036.00

0.11%

Aurobindo Pharma (BUY): Acquisition of Veritaz Healthcare marks India formulations

Buy: Aurobindo Pharma Ltd.

BOB Capital Markets Ltd.

ARBP acquired Veritaz Healthcare at 1x FY22E sales (9.8x EBITDA), marking its foray into domestic formulations

Aurobindo Pharma Ltd. is trading below all available SMAs

Aurobindo Pharma Ltd.

28 Mar 2022

1036.00

0.11%

Aurobindo Pharma acquires Veritaz' domestic business for Rs 171 cr

Business Standard

Move marks Aurobindo's increasing focus on Indian market

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Aurobindo Pharma acquires Veritaz Healthcare for Rs 171 crore

Business Today | 28 Mar 2022 2 more

Aurobindo Pharma Ltd.

18 Feb 2022

1036.00

0.11%

AUROBINDO PHARMA LTD

Buy: Aurobindo Pharma Ltd.

Target

Geojit BNP Paribas

With a strong pipeline including injectable products, higher R&D expenses and strong cash flow generation, we remain positive on the stock and reiterate our BUY rating with a rolled forward target price of...

Aurobindo Pharma Ltd. is trading below all available SMAs

Aurobindo Pharma Ltd.

17 Feb 2022

1036.00

0.11%

Buy Aurobindo Pharma; target of Rs 875: Sharekhan

Moneycontrol

Sharekhan is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 875 in its research report dated February 10, 2022.

Aurobindo Pharma Ltd. is trading below all available SMAs

Aurobindo Pharma Ltd.

15 Feb 2022

1036.00

0.11%

Accumulate Aurobindo Pharma; target of Rs 759: Prabhudas Lilladher

Moneycontrol

Prabhudas Lilladher recommended accumulate rating on Aurobindo Pharma with a target price of Rs 759 in its research report February 10, 2022.

Aurobindo Pharma Ltd. has lost -33.14% in the last 1 Year

Accumulate Aurobindo Pharma; target of Rs 756: KR Choksey

Moneycontrol | 15 Feb 2022

Aurobindo Pharma Ltd.

11 Feb 2022

1036.00

0.11%

Will the Street reward Aurobindo Pharma's bet on domestic formulations?

Moneycontrol

The stock currently trades at a valuation of 6.6x FY23e EV/EBITDA, which is at a substantial discount to its Indian peers which have an exposure in the US market. A large part of the discount is due to the company's absence in the domestic branded generics business.

Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.

Aurobindo Pharma Ltd.

11 Feb 2022

1036.00

0.11%

Result Update:Aurobindo Pharma

Hold: Aurobindo Pharma Ltd.

Target

Axis Direct

Considering the overall increase in the competition, persistent price erosion in the US market (68% revenue from the US market), and higher frequency of USFDA inspection may lead to more surprise in upcoming quarters' results. Keeping this in view, we recommend HOLD with a Target Price of Rs..

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Aurobindo Pharma Ltd.

10 Feb 2022

1036.00

0.11%

Earnings Call for Q3FY22 of Aurobindo Pharma

Conference Call with Aurobindo Pharma Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.

audio

Aurobindo Pharma Ltd.

10 Feb 2022

1036.00

0.11%

AUROBINDO PHARMA

Accumulate: Aurobindo Pharma Ltd.

Target

Prabhudas Lilladhar

We cut our FY23E EPS est. by 12% and FY24E EPS est. by 8% to factor in lower margins and US sales. Aurobindo Pharma's (ARBP) 9MFY22 performance was weak, given cost headwinds and lower US sales. We believe cost pressures have stabilized and margin trajectory should improve from FY23. However, pick up in US sales hinge on timely niche approvals along with stabilization of pricing pressure in base business. ARBP has multiple growth drivers in place with investments in vaccines, injectables, biosimilars...